By Elaine Rigoli
Tampa, Fla., July 13 - Elusys Therapeutics, Inc. announced that it has raised $11 million in an extension of its series D financing round, bringing the total of the round to $23 million.
As part of this extension, MedImmune Ventures Inc. joined current investors including Essex Woodlands Health Ventures LLC, Crescendo Ventures and Invesco Private Capital.
"Elusys is very pleased to welcome MedImmune Ventures to our investor group. This new venture funding will accelerate the development of our HP antibody pipeline targeting drug-resistant infections. Our lead HP antibody candidate, ETI-211, targets methicillin-resistant staphylococcus aureus infections and has shown significant in-vivo efficacy," president and chief executive officer Elizabeth Posillico said in a news release.
Elusys is a privately held biopharmaceutical company based in Pine Brook, N.J.
| Issuer: | Elusys Therapeutics, Inc.
|
| Issue: | Series D financing
|
| Amount: | $23 million
|
| Investors: | MedImmune Ventures Inc., Essex Woodlands Health Ventures LLC, Crescendo Ventures and Invesco Private Capital
|
| Announcement date: | July 13
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
